Milrinone Tillomed (Milrinone)

Milrinone works by selectively inhibiting phosphodiesterase‑3, which raises intracellular cyclic AMP levels in cardiac and vascular smooth‑muscle cells. The increase in cAMP enhances calcium entry into heart muscle, producing a stronger contraction, while simultaneously relaxing blood vessels to lower systemic vascular resistance.

The dose of Milrinone Tillomed is determined by the prescribing clinician based on the patient’s clinical status, weight, and renal function. The medication is administered intravenously as a continuous infusion, and the exact rate is individualized for each patient.

Safety data for Milrinone in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Milrinone Tillomed, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative inotropic agent is dobutamine, a beta‑adrenergic agonist. Milrinone offers both inotropic support and vasodilation through PDE3 inhibition, whereas dobutamine primarily increases contractility with less vasodilatory effect. Milrinone may be preferred when afterload reduction is also desired, but it carries a higher risk of arrhythmias in certain patients.

Milrinone Tillomed must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and sterility.

Milrinone is given as an intravenous infusion. After a possible loading dose, a continuous infusion is started, with the rate adjusted by the treating physician according to hemodynamic response and tolerability. Administration takes place in a monitored setting such as an intensive‑care unit.

The most serious adverse events include severe ventricular arrhythmias, myocardial ischemia, profound hypotension, and rare anaphylactic reactions. Continuous cardiac monitoring and blood pressure checks are essential to detect these complications early.

Milrinone is contraindicated in patients with severe hypotension, obstructive cardiomyopathy, recent myocardial infarction with ongoing ischemia, or known hypersensitivity to the drug. Caution is also advised in individuals with significant renal impairment or uncontrolled electrolyte abnormalities.